[Michaelangelica]

What's New in Depression May 1, 2008

How much do you need to worry that patients you are treating for depression will go on to develop Alzheimer disease (AD)? Two recently published studies raised further concerns about the association and seemed to underline the difficulty of making the diagnosis of AD ahead of time.

In the April 8 issue of Neurology, investigators from Erasmus Medical Center, Rotterdam, reported an increased risk for developing Alzheimer that was more than triple in patients who had early-onset depression and more than double in those who had late-onset depression.

iMarketing Automation

[Michaelangelica]

We look forward to your posts Dr.Erfan

Impaired Insulin Response Linked to Alzheimer's Disease

elderly, Alzheimer's diseaseImpaired insulin response appears to be involved in the development of Alzheimer's disease, according to a long-term population-based study.

Researchers analyzed data for more than 2,200 men who underwent glucose tolerance testing at the age of 50. After a follow-up at an average age of 32 years, 394 men developed dementia or mental impairments, including 102 with confirmed Alzheimer's disease and 57 with confirmed vascular dementia.

Impaired Insulin Response Linked to Alzheimer's Disease - Articles

[Michaelangelica]

Alzheimer's Disease Risks Gender Specific: Women With Depression, Men With Stroke

ScienceDaily (May 2, 2008) — The risks of developing Alzheimer's disease differ between the sexes, with stroke in men, and depression in women, critical factors, suggests research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.
. . .

Just over one in three reverted to normal levels of cognitive agility. Progression from mild cognitive impairment to dementia was more likely among those who were depressed and who were taking anticholinergic drugs, which influence chemical signalling in the brain.

A variation in the ApoE gene, a known risk factor for dementia, was also more common among those whose mild cognitive impairment progressed. But risk factors also differed between the sexes, the results showed.

Men with mild cognitive impairment were more likely to be overweight, diabetic, and to have had a stroke. Men who had had a stroke were almost three times as likely to progress. Women with mild cognitive impairment were more likely to be in poorer general health, disabled, suffering from insomnia and to have a poor support network.

Women unable to perform routine daily tasks, which would allow them to live without assistance, were 3.5 times as likely to progress. And those who were depressed were twice as likely to do so. Stroke was not a risk factor for women, despite a similar rate of occurrence in both sexes.

Alzheimer's Disease Risks Gender Specific: Women With Depression, Men With Stroke

[Michaelangelica]

King Lear
One of the first documented Alzheimer's sufferers??

Pomegranates
I love pomegranates but rarely if ever eat them. I think they are more popular in the UK. They are such pretty fruit and trees and may help Alzheimer's.

SEE:-
Pomegranate sauce offers marinade potential for industry
and

Pomegranate juice may cut Alzheimer's risk
By Stephen Daniells

03-Oct-2006 - A daily glass of antioxidant-rich pomegranate juice could halve the build-up of harmful proteins linked to Alzheimer's disease, says a new animal study from the USA.

Pomegranate juice may cut Alzheimer's risk


Anyone want to summarise all the foods and wines that are good for Alzheimer's we have discovered so far?
how about The Hypography Alzheimer's Cookbook"?

New B12 Delivery Offers Possible Help for Dementia and Alzheimer's

Download this press release as a PDF document.

FORT LAUDERDALE, Florida, April 30 /PRNewswire-HISPANIC PR WIRE/ -- Alzheimer's Disease touches many people. Statistics from the Alzheimer's Association indicate that as many as 5.2 million people in the United States are living with Alzheimer's and every 71 seconds, someone develops Alzheimer's, including Hispanics. It is a progressive condition that causes problems with memory, thinking and behavior severe enough to affect work, lifelong hobbies, or social life.



Many people are unaware that Alzheimer's is also a fatal disease. In fact, it is the seventh leading cause of death in the United States alone. Alzheimer's, along with other dysfunctions of memory and thinking known as dementia, typically rob families and individuals of happiness and the ability to live their senior years to the fullest. Therefore, the search is on to find treatments that can help slow down or reverse the onset of these brain disorders.

Many people are unaware that Alzheimer's is also a fatal disease


Research indicates that something as simple as vitamin B12 may be instrumental to that end, but the challenge has been finding ways to deliver B12 in sufficient quantities to the blood stream and cerebral spinal fluid. Now Nascobal(R) Nasal Spray, (Welcome to Nascobal - A QOL Medical Company) an FDA approved B12 product of QOL Medical, has been shown in clinical trials to significantly increase blood levels and to increase the CSF levels ten-fold when compared to the typical treatment of intramuscular injections.

Importance of B12
Vitamin B12 is an important vitamin for a person's health. It plays a vital role in the formation of red blood cells and in the health of nerve tissue. B12 works with folic acid in the synthesis of DNA and red blood cells and is important in maintaining the health of the insulation sheath (myelin sheath) that surrounds nerve cells. A deficit of B12 results in neurological dysfunction, including memory loss, trouble concentrating, anemia, and even vascular problems. Vitamin B12 deficiency is very common among older adults and those with stomach problems that compromise absorption of the vitamin.

Hispanic PR Wire - New B12 Delivery Offers Possible Help for Dementia and Alzheimer's
and
Welcome to Nascobal - A QOL Medical Company

[Michaelangelica]

Samaritan Pharmaceuticals (OTCBB:SPHC), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office.

The hallmark of Alzheimer's disease is plaque formation in areas of the brain that control memory and thinking skills.
Plaque can cause swelling and bumps on nerve cells, making it hard or even impossible for the cells to communicate.
While the cause of Alzheimer's disease still remains unknown, a growing number of researchers are indicating that plaque formation and accumulation may play a role.

Caprospinol Studies:

Caprospinol cleared beta-amyloid plaque formation and restored memory capacity in-vivo, confirming in-vitro studies showing Caprospinol binds beta-amyloid directly and inhibits the formation of neurotoxic amyloid-derived diffusible ligands (ADDLs) by forming stable heavy complexes with the peptide.
In addition, the studies demonstrated Caprospinol protects mitochondria function, thus protecting cell viability and decreased cell death.
Studies have demonstrated Caprospinol may not only slow down Alzheimer's but may also reverse plaque-related brain injuries associated with the mind-robbing disease of Alzheimer's

Patent Claims Allowed Covering Samaritan's Alzheimer's Memory Recovery Drug In Australia

[HydrogenBond]

I like to speculate. If you look at depression, it narrows the mind. For example, one may lose interests, meaning the range of thinking sort of defaults to the psycho-drama loop associated with the depression. It may also limit physical activity and the blood pumped to the brain. If we combine this with the correlation that keeping the mind active helps to prevent Alzheimer's, one can see a connection between conscious focus, and system wide neurons usage or not. The depression implies system wide neural atrophy because the mind is not exercising memory. A study might address whether Alzheimer's patients stemming from depression are able to remember their depression better than other memory.

[Monomer]

Flavonoids May Help Treat Alzheimer's

Flavonoids, compounds found in many fruits and vegetables, may be able to battle the ravages of Alzheimer's disease, a new study suggests.

In experiments with mice, two flavonoids called luteolin and diosmin reduced levels of beta-amyloid, which forms the harmful plaques that build up in the brains of those with Alzheimer's disease.

The research team would like to use the two flavonoids to see if they can reduce amyloid plaque in humans, since they believe flavonoids would be safe and have few side effects compared with drugs that are being developed to reduce amyloid plaque.

Rezai-Zadeh also thinks that flavonoids, which have strong antioxidant properties, might guard against Alzheimer's. "A lot of these compounds can be derived from the diet, and they may have preventive effects against Alzheimer's disease," he said. "Increasing the flavonoids in your diet may help reduce the risk of Alzheimer's."

"The question is, can we use these flavonoids in people that have cognitive impairment?" Rezai-Zadeh said. "That's the million-dollar question."

In the study, Rezai-Zadeh's team used a mouse model of Alzheimer's disease to test their theory. Using, luteolin and diosmin, the researchers were able to reduce the levels of beta-amyloid in the rodents' brains.

In addition, the researchers found these two molecules were targeting a protein called presenilin-1, which has been linked to a genetic cause of Alzheimer's disease. These findings could lead to a new approach for treating Alzheimer's patients, they said.

[Michaelangelica]

Listen Now - 12052008 |Download Audio - 12052008

A recent study by French researchers suggests that the risk of developing Alzheimer's disease differs between the sexes, with stroke in men and depression in women being critical factors. And a group of researchers in Canada have come up with a set of tests which seem to be able to give a high degree of confidence that someone has Alzheimer's.

Show Transcript | Hide Transcript

AM - Research questions stockpiling of bird flu drugs

[Michaelangelica]

Latest news
25 million affected by dementia, as Terry Pratchett steps-up fight against the disease
20th May 2008

Terry Pratchett An Alzheimer’s Research Trust survey has revealed that 25 million people in the UK are touched by dementia. The poll results are released as Terry Pratchett announces he is to become a Patron of the Alzheimer’s Research Trust.

The YouGov poll, commissioned by the Alzheimer’s Research Trust, found that 42% of the population – 25 million people – know a close friend, family member or someone else with dementia. 700,000 people in the have the disease.

Latest news - Alzheimer's Research Trust
Check out if your local (Uk) member is supporting this
UK Parliament - Early Day Motions By Details

What is the Canadian & USA Alzheimer's Charity/Research body?

[Michaelangelica]

These two reports are abit scary

Latest news
Scottish scientists explain dementia, as poll reveals half of all Scots affected.
28th May 2008

Calum Sutherland Scotland’s top scientists are presenting their research on dementia to the public, as an Alzheimer’s Research Trust poll reveals that almost half of all Scots are touched by the disease.

Latest news - Alzheimer's Research Trust

Latest news
Report finds dementia crisis worsening, as calls grow for more dementia research funding
28th May 2008

Rebecca Wood of the Alzheimer's Research Trust The King’s Fund’s ‘Paying the Price’ report shows the UK to be facing a dementia crisis, underlining the urgent need for further research into Alzheimer’s disease and other dementias.

The report forecasts that in the next 18 years the 582,827 people with dementia in England alone is set to increase by 61% to just shy of 1 million.

Latest news - Alzheimer's Research Trust

Some Good news:-

Latest news
Anti-inflammatory drugs may reduce dementia risk
29th May 2008

drugs US researchers have reported that different types of anti-inflammatory drugs known as non-steroidal anti-inflammatory drugs (NSAIDs), may be equally effective at reducing the risk of Alzheimer’s disease.
The research, published in Neurology, found that the risk reduction was independent of whether the person was taking ibuprofen, aspirin or naproxen.

Previous research indicated that a particular group of NSAIDs, including ibuprofen, might be more beneficial than another group that includes naproxen and aspirin.
The researchers examined data from 13,499 people and found that those who used NSAIDs had a 23% lower risk of developing Alzheimer’s disease compared to those who had never used NSAIDs.

The study's author, Dr Peter Zandi, from the Johns Hopkins Bloomberg School of Public Health in Baltimore, said, “This is an interesting finding because it seems to challenge a current theory that the NSAID group which includes ibuprofen may work better in reducing a person’s risk of Alzheimer’s.

Latest news - Alzheimer's Research Trust